Point72 Asset Management’s Audentes Therapeutics BOLD Stock Holding History
Bought
Maintained
Sold
Other funds holding BOLD
Point72 Asset Management's BOLD Position: Q4 2019 in Review
Point72 Asset Management sold out of Audentes Therapeutics (BOLD) in Q4 2019, closing a stake of 241,100 shares — an estimated $6.77M sold.
Point72 Asset Management first reported a position in BOLD in Q2 2017 and held it in 5 quarters. The position peaked at $10.7M in Q1 2019. 187 funds tracked by Wall St. Rank hold BOLD as of Q4 2019.
- Point72 Asset Management reported no remaining Audentes Therapeutics position as of Q4 2019 after selling out during the quarter.
- Point72 Asset Management sold 241,100 Audentes Therapeutics shares in Q4 2019, an estimated $6.77M.
- Point72 Asset Management first reported a position in Audentes Therapeutics in Q2 2017 and held it in 5 quarters.
- Point72 Asset Management's Audentes Therapeutics position peaked at $10.7M in Q1 2019.
- 187 funds tracked by Wall St. Rank held Audentes Therapeutics as of Q4 2019.
Based on Point72 Asset Management's 13F filing for Q4 2019, filed 14 Feb 2020.